关键信息
-
基因名
SLC15A1
- 应用
-
别名
+peptide cotransporter; HPECT1; HPEPT1; Human peptide transporter (HPEPT1) mRNA complete cds; Intestinal H; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter; Oligopeptide transporter small intestine isoform; PEPT1; Peptide transporter 1; S15A1_HUMAN; Slc15a1; small intestine isoform; Solute carrier family 15 (oligopeptide transporter) member 1; Solute carrier family 15 member 1
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P46059
-
表达区间
473-572 aa
-
氨基酸序列
VKDGLNQKPEKGENGIRFVNTFNELITITMSGKVYANISSYNASTYQFFPSGIKGFTISSTEIPPQCQPNFNTFYLEFGSAYTYIVQRKNDSCPEVKVFE
-
分子量
36.74 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
SLC15A1, also known as the peptide transporter 1 (PepT1), is a member of the solute carrier family responsible for the transport of di- and tripeptides as well as certain drugs across cellular membranes. Its significance lies in its role in nutrient absorption in the intestines and renal tubular reabsorption. Alterations in SLC15A1 function can lead to various health implications, including malabsorption syndromes and impacts on pharmacokinetics for certain medications. Research involving the recombinant expression of SLC15A1 allows scientists to investigate its structure-function relationships, mechanisms of substrate specificity, and the effects of genetic variations. This understanding is essential for developing therapeutic strategies to enhance drug delivery and improve nutrient absorption. Moreover, as SLC15A1 can influence the bioavailability of peptide-based medications and certain antibiotics, its study has implications for optimizing treatment regimens. Recombinant SLC15A1 proteins can serve as valuable tools for high-throughput screening of new drug candidates as well as for elucidating the transport mechanisms at play in various physiological and pathological conditions. Thus, the ongoing research into SLC15A1 and its recombinant forms is pivotal in the fields of pharmacology, nutrition, and biomedical research.
